fludesoxyglucose (18f) curium 185 mbq/ml sol. inj. i.v. flac.
iba pharma sa-nv - fludésoxyglucose (f-18) - solution injectable - 185 mbq/ml - fludésoxyglucose (f-18) - fludeoxyglucose (18f)
laxoberon 7.5 mg/ml gtts buv. sol. flac. compte-gouttes
opella healthcare belgium sa-nv - picosulfate de sodium 0,75 g/100 ml - solution buvable en gouttes - 7,5 mg/ml - picosulfate de sodium 7.5 mg/ml - sodium picosulfate
rhinospray nez bouché 1.18 mg/ml sol. pulv. nas. flac. pulv.
opella healthcare belgium sa-nv - chlorhydrate de tramazoline monohydraté 0,125 g/100 g - eq. chlorhydrate de tramazoline 0,118 g/100 g - solution pour pulvérisation nasale - 1,18 mg/ml - chlorhydrate de tramazoline 1.18 mg/g - tramazoline
rhinospray eucalyptus nez bouché 1.18 mg/ml sol. pulv. nas. flac. pulv.
opella healthcare belgium sa-nv - chlorhydrate de tramazoline monohydraté 0,125 g/100 g - eq. chlorhydrate de tramazoline 0,118 g/100 g - solution pour pulvérisation nasale - 1,18 mg/ml - chlorhydrate de tramazoline 1.18 mg/g - tramazoline
pylclari
curium pet france - piflufolastat (18f) - néoplasmes prostatiques - produits radiopharmaceutiques de diagnostic - ce médicament est destiné à un usage diagnostique uniquement. pylclari is indicated for the detection of prostate-specific membrane antigen (psma) positive lesions with positron emission tomography (pet) in adults with prostate cancer (pca) in the following clinical settings:primary staging of patients with high-risk pca prior to initial curative therapy,to localize recurrence of pca in patients with a suspected recurrence based on increasing serum prostate-specific antigen (psa) levels after primary treatment with curative intent. pylclari is indicated for use with positron emission tomography (pet).